Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies

被引:50
作者
Frumovitz, Michael
Sood, Anil K.
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA
关键词
vascular endothelial growth factor (VEGF); angiogenesis; gynecologic cancer;
D O I
10.1016/j.ygyno.2006.10.062
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vascular endothelial growth factor (VEGF) plays a critical role in angiogenesis, which is required for tumor growth and metastasis. In this article, a review of the functional and biological roles of the VEGF pathway in driving angiogenesis and growth of gynecologic malignancies was performed. Based on the biological functions of VEGF, multiple approaches for targeting the VEGF/VEGF-receptor complex have been developed and many of these have demonstrated substantial activity in preclinical models. These promising data have led to rapid clinical development of VEGF-targeted agents. Therefore, we also assessed the status of VEGF-targeted therapies and associated toxicities in gynecologic malignancies. However, many questions remain related to optimal dosing, sequencing of therapies, management of toxicities, appropriate patient selection, and assessment of response, which will require further studies. Nevertheless, VEGF-targeted therapies offer hope for improving the outcome of cancer patients. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:768 / 778
页数:11
相关论文
共 81 条
[11]   Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer [J].
Cohn, David E. ;
Valmadre, Sue ;
Resnick, Kimberly E. ;
Eaton, Lynne A. ;
Copeland, Larry J. ;
Fowler, Jeffrey M. .
GYNECOLOGIC ONCOLOGY, 2006, 102 (02) :134-139
[12]  
Cooper BC, 2002, CLIN CANCER RES, V8, P3193
[13]   Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors [J].
Dupont, J ;
Bienvenu, B ;
Aghajanian, C ;
Pezzulli, S ;
Sabbatini, P ;
Vongphrachanh, P ;
Chang, C ;
Perkell, C ;
Ng, K ;
Passe, S ;
Breimer, L ;
Zhi, LG ;
DeMario, M ;
Spriggs, D ;
Soignet, SL .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3366-3374
[14]   Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy [J].
Dvorak, HF .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4368-4380
[15]  
DVORAK HF, 1995, AM J PATHOL, V146, P1029
[16]   Vascular endothelial growth factor as a target for anticancer therapy [J].
Ferrara, N .
ONCOLOGIST, 2004, 9 :2-10
[17]   The biology of VEGF and its receptors [J].
Ferrara, N ;
Gerber, HP ;
LeCouter, J .
NATURE MEDICINE, 2003, 9 (06) :669-676
[18]   WHAT IS THE EVIDENCE THAT TUMORS ARE ANGIOGENESIS DEPENDENT [J].
FOLKMAN, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (01) :4-6
[19]   ROLE OF THE FLT-1 RECEPTOR TYROSINE KINASE IN REGULATING THE ASSEMBLY OF VASCULAR ENDOTHELIUM [J].
FONG, GH ;
ROSSANT, J ;
GERTSENSTEIN, M ;
BREITMAN, ML .
NATURE, 1995, 376 (6535) :66-70
[20]  
Fong GH, 1999, DEVELOPMENT, V126, P3015